Staels, Bart

Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription

Raspé, E., Duez, H., Mansén, A., Fontaine, C., Fiévet, C., Fruchart, J.-C., Vennström, B., & Staels, B. (2002) · Journal of Lipid Research

Lipid metabolism and disordersCholesterol and Lipid Metabolism

Cited by 183

Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury

Khandoudi, N., Delerive, P., Berrebi-Bertrand, I., Buckingham, R. E., Staels, B., & Bril, A. (2002) · Diabetes

Cardiac Ischemia and ReperfusionPeroxisome Proliferator-Activated Receptors

Cited by 174

Severe Atherosclerosis and Hypoalphalipoproteinemia in the Staggerer Mouse, a Mutant of the Nuclear Receptor RORα

Mamontova, A., Séguret-Macé, S., Esposito, B., Chaniale, C., Bouly, M., Delhaye-Bouchaud, N., Luc, G., Staels, B., Duverger, N., Mariani, J., et al. (1998) · Circulation

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 172

When the Clock stops ticking, metabolic syndrome explodes

Staels, B. (2006) · Nature Medicine

Circadian rhythm and melatoninDietary Effects on Health

Cited by 167

Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?

Hannou, S. A., Wouters, K., Paumelle, R., & Staels, B. (2015) · Trends in Endocrinology & Metabolism

Genetic Associations and EpidemiologyGenomics and Chromatin Dynamics

Cited by 159

Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution

Haas, J. T., Vonghia, L., Mogilenko, D. A., Verrijken, A., Molendi-Coste, O., Fleury, S., Deprince, A., Nikitin, A., Woitrain, E., Ducrocq-Geoffroy, L., et al. (2019) · Nature Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 155

The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression

Miranda, M. X., van Tits, L. J., Lohmann, C., Arsiwala, T., Winnik, S., Tailleux, A., Stein, S., Gomes, A. P., Suri, V., Ellis, J. L., et al. (2015) · European Heart Journal

Cholesterol and Lipid MetabolismSirtuins and Resveratrol in Medicine

Cited by 153

Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

Vu-Dac, N., Gervois, P., Torra, I. P., Fruchart, J. C., Kosykh, V, Kooistra, T., Princen, H. M., Dallongeville, J., & Staels, B. (1998) · Journal of Clinical Investigation

Lipid metabolism and disordersRetinoids in leukemia and cellular processes

Cited by 143

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

Pawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., Lebherz, C., Lefebvre, P., & Staels, B. (2014) · Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 141

Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-

Kockx, M., Gervois, P. P., Poulain, P., Derudas, B., Peters, J. M., Gonzalez, F. J., Princen, H. M. G., Kooistra, T., & Staels, B. (1999) · Blood

Peroxisome Proliferator-Activated ReceptorsBlood properties and coagulation

Cited by 139

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

Hennuyer, N., Duplan, I., Paquet, C., Vanhoutte, J., Woitrain, E., Touche, V., Colin, S., Vallez, E., Lestavel, S., Lefebvre, P., et al. (2016) · Atherosclerosis

Cholesterol and Lipid MetabolismPeroxisome Proliferator-Activated Receptors

Cited by 132

Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence

Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 130

PPARs in liver physiology

Berthier, A., Johanns, M., Zummo, F. P., Lefebvre, P., & Staels, B. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid Metabolism

Cited by 125

Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions

Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 124

PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle

Hondares, E., Pineda-Torra, I., Iglesias, R., Staels, B., Villarroya, F., & Giralt, M. (2007) · Biochemical and Biophysical Research Communications

Peroxisome Proliferator-Activated ReceptorsAdipose Tissue and Metabolism

Cited by 120

Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin

Lefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., Vanhoutte, J., Woitrain, E., Hennuyer, N., Mazuy, C., et al. (2017) · JCI Insight

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 117

Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice

Wouters, K., van Bilsen, M., van Gorp, P. J., Bieghs, V., Lütjohann, D., Kerksiek, A., Staels, B., Hofker, M. H., & Shiri-Sverdlov, R. (2010) · FEBS Letters

Liver Disease Diagnosis and TreatmentCholesterol and Lipid Metabolism

Cited by 109

Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis

Brunham, L. R., Singaraja, R. R., Duong, M., Timmins, J. M., Fievet, C., Bissada, N., Kang, M. H., Samra, A., Fruchart, J.-C., McManus, B., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 102

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists

Yamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters

Peroxisome Proliferator-Activated ReceptorsHeterocyclic Compound Synthesis and Bioactivity

Cited by 84

The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids

Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports

Gut microbiota and healthDiabetes Treatment and Management

Cited by 84

Abundant adrenal-specific transcription of the human P450c21A “pseudogene.”

Bristow, J., Gitelman, S. E., Tee, M. K., Staels, B., & Miller, W. L. (1993) · Journal of Biological Chemistry

Adrenal Hormones and DisordersSexual Differentiation and Disorders

Cited by 84

Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor α-dependent pathway

Edgar, A. D., Tomkiewicz, C., Costet, P., Legendre, C., Aggerbeck, M., Bouguet, J., Staels, B., Guyomard, C., Pineau, T., & Barouki, R. (1998) · Toxicology Letters

Peroxisome Proliferator-Activated ReceptorsDrug-Induced Hepatotoxicity and Protection

Cited by 71

The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis

Ploton, M., Mazuy, C., Gheeraert, C., Dubois, V., Berthier, A., Dubois-Chevalier, J., Maréchal, X., Bantubungi, K., Diemer, H., Cianférani, S., et al. (2018) · Journal of Hepatology

Drug Transport and Resistance MechanismsMetabolism, Diabetes, and Cancer

Cited by 63

Control of Cell Identity by the Nuclear Receptor HNF4 in Organ Pathophysiology

Dubois, V., Staels, B., Lefebvre, P., Verzi, M., & Eeckhoute, J. (2020) · Cells

Liver physiology and pathologyNuclear Receptors and Signaling

Cited by 63